Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annu...(-101 trodusquemine results are exp...),Health

are expected to enable further study of trodusquemine to establish the

primary pharmacodynamic impacts of the drug (improvement of abnormal

glucose tolerance and appetite suppression) and to fully validate its

proof-of-concept in multiple-dose clinical studies.

-- It was also noted that Genaera is closing enrollment in the 101 Study

with the 40 mg/m2 cohort due to the occurrence of nausea which although

transient, was felt to be drug related. The Company saw no medical

need, at this point in development, to take Study 101 to the point of

organ toxicity because single doses of 40 mg/m2 are well above the

anticipated clinical effect dose.

-- A second poster presentation of preclinical data, "Trodusquemine is a

Protein Tyrosine Phosphatase 1B Inhibitor that Causes Differential

Weight Loss," provides additional positive data and confirms the high

level of selectivity of MSI-1436 as a powerful inhibitor of PTP-1B when

compared to a wide range of enzymatic and non-enzymatic targets. These

results provide further support for its potential as a safe and

effective therapeutic for the treatment of type 2 diabetes and obesity.

-- Additionally, since MSI-1436 does not affect the targets (i.e. DPP-IV,

CB1, 5HT2C or NPYR) of other major drugs in this area, we anticipate

the potential for additive or synergistic effects of treating patients

with a combination of MSI-1436 and these other therapies.

"Our first clinical trial of MSI-1436 was a successful study as we achieved all of the goals we set out to reach in the 101 trial and found our drug to be safe and well tolerated," commented Jack Armstrong, President and Chief Executive Officer of Genaera. "A careful analysis of the data strongly reinforces our continued optimism and our intention to move forward with MSI- 14
'/>"/>